AgeX Therapeutics, Inc. (AGE): Price and Financial Metrics
AGE Price/Volume Stats
|Current price||$0.78||52-week high||$1.00|
|Prev. close||$0.76||52-week low||$0.37|
|Day high||$0.79||Avg. volume||22,374|
|50-day MA||$0.75||Dividend yield||N/A|
|200-day MA||$0.66||Market Cap||29.42M|
AGE Stock Price Chart Interactive Chart >
AGE Stock Summary
- With a price/sales ratio of 792.76, AGEX THERAPEUTICS INC has a higher such ratio than 99.35% of stocks in our set.
- AGE's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 6.51% of US stocks.
- Revenue growth over the past 12 months for AGEX THERAPEUTICS INC comes in at -47.06%, a number that bests merely 5.62% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to AGEX THERAPEUTICS INC, a group of peers worth examining would be BIAF, ENZN, CDZI, OI, and EAF.
- Visit AGE's SEC page to see the company's official filings. To visit the company's web site, go to www.agexinc.com.
AGE Valuation Summary
- In comparison to the median Healthcare stock, AGE's price/earnings ratio is 109.74% lower, now standing at -2.6.
- Over the past 59 months, AGE's price/sales ratio has gone up 722.5.
Below are key valuation metrics over time for AGE.
AgeX Therapeutics, Inc. (AGE) Company Bio
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.
AGE Latest News Stream
|Loading, please wait...|
AGE Latest Social Stream
View Full AGE Social Stream
Latest AGE News From Around the Web
Below are the latest news stories about AGEX THERAPEUTICS INC that investors may wish to consider to help them evaluate AGE as an investment opportunity.
HUNTSVILLE, Ala. & ALAMEDA, Calif., August 30, 2023--Serina Therapeutics, Inc. ("Serina"), a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson’s Disease and other neurological diseases, entered into a merger agreement with AgeX Therapeutics, Inc. (NYSE American: AGE) ("AgeX") on August 29, 2023, under which Serina will merge with a wholly-owned subsidiary of AgeX in an all-stock transaction. The combined company will continue u
ALAMEDA, Calif., August 14, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023.
ALAMEDA, Calif., July 24, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 24, 2023, AgeX issued to Juvenescence Limited 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loa
ALAMEDA, Calif., July 21, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported that on July 21, 2023, AgeX and Juvenescence Limited entered into an Exchange Agreement pursuant to which AgeX agreed to issue to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 M
ALAMEDA, Calif., May 23, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on May 17, 2023 it received a notice from the staff of the NYSE American (the "Exchange") indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003(a)(i), (ii) and (iii)
AGE Price Returns